Novavax, a biotechnology company committed to development and bringing to market next-generation vaccines for critical infectious diseases, announced that it has finalized its ongoing regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine (NVX-CoV2373). This submission for Conditional Marketing Authorization (CMA) is the first authorization in the United Kingdom (UK) for a protein-based COVID-19 vaccine. Following this submission, Novavax plans to also complete further regulatory filings in Europe, Canada, Australia, New Zealand, and with the World Health Organization (WHO).
Read more here.